The Influence of [18F]PMPBB3 and [18F]THK5351 PET Distribution Patterns on Post-stroke Cognitive Impairment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-01

Study Completion Date

2024-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background and objects： Neuroinflammation is an active process detectable in the earliest stages of the neurodegeneration pathway. On the other hand, significant neuroinflammation, such as reactive astrocytosis, can also be observed after cerebral ischemic injury. \[18F\]THK5351 can monitor the neuroinflammatory process due to its high affinity to astrogliosis, and \[18F\]PMPBB3 is the novel tau protein radiotracer without significant off-target binding to MAO-B. The investigators hypothesize that the neuroinflammation after acute stroke may induce the tau protein accumulation. In the current proposal, our aims are to 1) explore the interaction between neuroinflammation and tau protein accumulation in acute stroke patients by applying both the \[18F\]PMPBB3 and \[18F\]THK5351 PET images and 2) determine their influence on the longterm stroke outcome and cognitive performance.

Method： The prospective project plans to recruit 2 groups of participants: one is patients with first-ever acute stroke (Group A, n=50), and the other is healthy people as the control group (Group B, n=30). Within 3 weeks of stroke, \[18F\]THK5351 and \[18F\]PMPBB3 PET will be done for imaging cerebral neuroinflammation and tau protein distribution. Brain MRI for obtaining structural and functional information will be done within 3 weeks and 3 months after stroke. Clinical and cognitive outcome will be evaluated at week 3 and months 3 and 12. In addition, APOE genotyping and carotid ultrasound will be performed as well. By obtaining the neuroimaging information, such as severity of white matter change and infarction, cortical and hippocampal atrophy, and SUVRs of \[18F\]THK5351 and \[18F\]PMPBB3 PET, the study will be able to investigate the complex interaction between neuroinflammation and tau protein accumulation after stroke, and also evaluate their influence on structural changes, stroke outcome and cognitive performance. Group comparisons will be performed using the Chi-square test, independent t test, Mann-Whitney U test, and multiple linear regression, where appropriate.

Anticipation： In this project, the investigators will be able to identify the distribution patterns of neuroinflammation and tau protein accumulation after actue stroke. Secondly, the investigators expect that the presence of neuroinflammation and tau protein accumulation will interfere with the functional connectivity. Finally, the investigators expect that the extent of neuroinflammation and tau protein is correlated with stroke outcome and post-stroke cognitive impairment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects.(Positron Emission Tomograph )

NCT02686216

Alzheimer's Disease

COMPLETED PHASE1

Topography Staging and Dual Phase Image Quantification of Tau PET in Cognitive Impairment Subjects

NCT04169126

Alzheimer's Disease

UNKNOWN PHASE2

The Influence of Sequential Tau Protein and Amyloid Plaque Imaging Changes on Stroke Prognosis and Cognitive Outcome

NCT04572477

Post-stroke Dementia, Vascular Mild Cognitive Impairment

UNKNOWN PHASE2

Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

NCT01209156

Alzheimer Disease

COMPLETED PHASE1

18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls

NCT03625128

Alzheimer's Disease Cortical Basal Syndrome Frontotemporal Dementia +2 more

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post-stroke Cognitive Impairment Neuroinflammation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

A. Group A: Patients with acute stroke/TIA, n=50. B. Group B: Normal control, n=30.

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PMPBB3

1. Name: \[18F\] PMPBB3，\[18F\]1-Fluoro-3-((2-((1E,3E)-4-(6-(methylamino)pyridin-3-yl)buta-1,3-dien-1-yl)ben
2. Dosage form: intravenous injection
3. Dose(s): 7mCi
4. Dosing schedule: Visit 2
5. Mechanism of action (if known): high affinity radiotracer for the tau protein
6. Pharmacological category：Radio pharmaceutical

Group Type OTHER

PMPBB3

Intervention Type DRUG

F-18 PMPBB3 PET Imaging

THK5351

Intervention Type DRUG

F-18 THK5351 PET Imaging

THK

1. Name: \[18F\]THK5351，(S)-6-\[(3-Fluoro-2-hydroxy)propoxy\]-2-(2-Methylaminopyrid-5-yl)-quinoline
2. Dosage form: intravenous injection
3. Dose(s): 10mCi
4. Dosing schedule: Visit 2
5. Mechanism of action (if known): high affinity radiotracer for the tau protein
6. Pharmacological category：Radio pharmaceutical

Group Type OTHER

PMPBB3

Intervention Type DRUG

F-18 PMPBB3 PET Imaging

THK5351

Intervention Type DRUG

F-18 THK5351 PET Imaging

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PMPBB3

F-18 PMPBB3 PET Imaging

Intervention Type DRUG

THK5351

F-18 THK5351 PET Imaging

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males or females with age \>= 20 years old.
* Having acute cerebral stroke or transient ischemic attack in recent 1 month.
* Female subjects of childbearing potential must practice effective contraception during the - Provision of signed informed consent from the subject and the subject's legally
* The subject has an appropriate caregiver capable of accompanying the subject, if necessary.

* Males or females with age \>= 20 years old
* Without history of cerebral stroke or transient ischemic attack
* Without history of mild cognitive impairment or dementia
* Ability to participate in cognitive and neuroimaging assessments
* Female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception after the final study
* Provision of signed informed consent

Exclusion Criteria

* Presence of dementia diagnosis before the index stroke or at the initial screening
* History of vascular MCI (VaMCI)
* The Chinese version of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) score \>=104 at the initial screening 45.
* Life expectancy less than 1 year.
* Clinically significant abnormal laboratory values.
* Clinically significant or unstable medical or psychiatric illness.
* Epilepsy history.
* Cognitive impairment resulting from trauma or brain damage.
* Substance abuse or alcoholism in the past 3 months.
* Pregnant or becoming pregnant during the study (as documented by pregnancy testing at screening or at any date during the study according to the PI discretion) or current breast feeding.
* History of allergy to 18F-labelled radionucleic agents, such as \[18F\]PMPBB3 or \[18F\]THK5351.
* Subjects having high risks for the study according to the PI discretion.

* The Chinese version of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) score \>=104 at the initial screening 45.
* Life expectancy less than 1 year.
* Clinically significant abnormal laboratory values.
* Clinically significant or unstable medical or psychiatric illness.
* Epilepsy history.
* Cognitive impairment resulting from trauma or brain damage.
* Substance abuse or alcoholism in the past 3 months.
* Pregnant or becoming pregnant during the study (as documented by pregnancy testing at screening or at any date during the study according to the PI discretion) or current breast feeding.
* History of allergy to 18F-labelled radionucleic agents, such as \[18F\]PMPBB3 or \[18F\]THK5351.
* Subjects having high risks for the study according to the PI discretion.

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes